ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2020.05.105
◽
2020
◽
Vol 83
(5)
◽
pp. 1367-1374
◽
Cited By ~ 3
Author(s):
Andrew Blauvelt
◽
Kim A. Papp
◽
Joseph F. Merola
◽
Alice B. Gottlieb
◽
Nancy Cross
◽
...
Keyword(s):
Plaque Psoriasis
◽
Extension Study
◽
Severe Plaque Psoriasis
◽
Double Blinded
Download Full-text
Related Documents
Cited By
References
Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.3.supp.34
◽
2019
◽
Vol 3
◽
pp. S34
Author(s):
Andrew Blauvelt
◽
Kim A Papp
◽
Joseph F Merola
◽
Alice B Gottlieb
◽
Nancy Cross
◽
...
Keyword(s):
Plaque Psoriasis
◽
Extension Study
◽
Severe Plaque Psoriasis
◽
Double Blinded
Abstract not available.
Download Full-text
Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.3.supp.35
◽
2019
◽
Vol 3
◽
pp. S35
Author(s):
Kim A Papp
◽
Joseph F Merola
◽
Alice B Gottlieb
◽
Christopher EM Griffiths
◽
Kristina K Harris
◽
...
Keyword(s):
Quality Of Life
◽
Clinical Outcomes
◽
Plaque Psoriasis
◽
Extension Study
◽
Severe Plaque Psoriasis
◽
Double Blinded
Abstract not available.
Download Full-text
AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY
10.1136/annrheumdis-2019-eular.4166
◽
2019
◽
Cited By ~ 1
Author(s):
Andrew Blauvelt
◽
Kim a. Papp
◽
Joseph F. Merola
◽
Alice B. Gottlieb
◽
Nancy Cross
◽
...
Keyword(s):
Plaque Psoriasis
◽
Extension Study
◽
Severe Plaque Psoriasis
◽
Double Blinded
Download Full-text
A Multi-Center, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study Evaluating Efficacy and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2022.01.005
◽
2022
◽
Author(s):
Chunlei Zhang
◽
Kexiang Yan
◽
Qingchun Diao
◽
Qing Guo
◽
Hongzhong Jin
◽
...
Keyword(s):
Plaque Psoriasis
◽
Efficacy And Safety
◽
Severe Plaque Psoriasis
◽
Dose Ranging
◽
Double Blinded
Download Full-text
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
British Journal of Dermatology
◽
10.1111/bjd.18851
◽
2020
◽
Vol 182
(6)
◽
pp. 1348-1358
◽
Cited By ~ 18
Author(s):
A. Blauvelt
◽
K. Papp
◽
A. Gottlieb
◽
A. Jarell
◽
K. Reich
◽
...
Keyword(s):
Plaque Psoriasis
◽
Severe Plaque Psoriasis
◽
Speed Of Response
◽
Double Blinded
◽
Blinded Trial
Download Full-text
25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2021.06.329
◽
2021
◽
Vol 85
(3)
◽
pp. AB76
Author(s):
Bruce Strober
◽
Richard B. Warren
◽
Peter Foley
◽
Melinda Gooderham
◽
Diamant Thaçi
◽
...
Keyword(s):
Plaque Psoriasis
◽
Phase 3
◽
Severe Plaque Psoriasis
◽
Double Blinded
◽
Patient Subgroups
Download Full-text
Five-year open-label extension study of safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2016.02.977
◽
2016
◽
Vol 74
(5)
◽
pp. AB251
Keyword(s):
Children And Adolescents
◽
Plaque Psoriasis
◽
Extension Study
◽
Open Label
◽
Safety And Efficacy
◽
Severe Plaque Psoriasis
◽
Open Label Extension
Download Full-text
Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.5.supp.53
◽
2021
◽
Vol 5
(6)
◽
pp. s53
Author(s):
Andrew Blauvelt
◽
Lars Iversen
◽
Sandy McBride
◽
Melinda Gooderham
◽
Petra Staubach
◽
...
Keyword(s):
Plaque Psoriasis
◽
Severe Plaque Psoriasis
◽
Double Blinded
N/A
Download Full-text
Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.5.supp.15
◽
2021
◽
Vol 5
(1)
◽
pp. s15
Author(s):
RB Warren
◽
A Blauvelt
◽
J Bagel
◽
KA Papp
◽
P Yamauchi
◽
...
Keyword(s):
Plaque Psoriasis
◽
Efficacy And Safety
◽
Phase 3
◽
Active Comparator
◽
Severe Plaque Psoriasis
◽
Double Blinded
Abstract not available.
Download Full-text
Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.5.supp.16
◽
2021
◽
Vol 5
(1)
◽
pp. s16
Author(s):
B Strober
◽
JG Krueger
◽
N Magnolo
◽
R Vender
◽
DP Toth
◽
...
Keyword(s):
Plaque Psoriasis
◽
Phase 3
◽
Severe Plaque Psoriasis
◽
Double Blinded
Abstract not available.
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close